DOP2021000123A - Terapias de combinación triple para anti-envejecimiento - Google Patents
Terapias de combinación triple para anti-envejecimientoInfo
- Publication number
- DOP2021000123A DOP2021000123A DO2021000123A DO2021000123A DOP2021000123A DO P2021000123 A DOP2021000123 A DO P2021000123A DO 2021000123 A DO2021000123 A DO 2021000123A DO 2021000123 A DO2021000123 A DO 2021000123A DO P2021000123 A DOP2021000123 A DO P2021000123A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- mitochondrial
- therapeutic agent
- aging
- targets
- oxidative stress
- Prior art date
Links
- 230000003712 anti-aging effect Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 230000008437 mitochondrial biogenesis Effects 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 230000036542 oxidative stress Effects 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003244 pro-oxidative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780488P | 2018-12-17 | 2018-12-17 | |
| US201962804411P | 2019-02-12 | 2019-02-12 | |
| US201962834794P | 2019-04-16 | 2019-04-16 | |
| PCT/US2019/066553 WO2020131704A1 (en) | 2018-12-17 | 2019-12-16 | Triple combination therapies for anti-aging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000123A true DOP2021000123A (es) | 2021-08-15 |
Family
ID=71102298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000123A DOP2021000123A (es) | 2018-12-17 | 2021-06-17 | Terapias de combinación triple para anti-envejecimiento |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11918597B2 (enExample) |
| EP (1) | EP3897659A4 (enExample) |
| JP (1) | JP7641897B2 (enExample) |
| KR (1) | KR20210104830A (enExample) |
| CN (1) | CN113453690A (enExample) |
| AU (1) | AU2019402099B2 (enExample) |
| BR (1) | BR112021011964A2 (enExample) |
| CA (1) | CA3123850A1 (enExample) |
| CL (1) | CL2021001617A1 (enExample) |
| CO (1) | CO2021009008A2 (enExample) |
| CR (1) | CR20210351A (enExample) |
| DO (1) | DOP2021000123A (enExample) |
| EC (1) | ECSP21052757A (enExample) |
| IL (1) | IL284059B2 (enExample) |
| MX (1) | MX2021007347A (enExample) |
| PE (1) | PE20220499A1 (enExample) |
| PH (1) | PH12021551435A1 (enExample) |
| SG (1) | SG11202106532WA (enExample) |
| WO (1) | WO2020131704A1 (enExample) |
| ZA (1) | ZA202104254B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210072026A (ko) | 2018-10-02 | 2021-06-16 | 루넬라 바이오테크 인코포레이티드 | 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체 |
| EP3923941B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and ribociclib |
| BR112022022185A2 (pt) * | 2020-05-13 | 2022-12-13 | Lunella Biotech Inc | Derivados de miristoíla de 9-amino-doxiciclina para alvejar células-tronco cancerígenas e prevenir metástase |
| WO2025114970A1 (en) * | 2023-11-30 | 2025-06-05 | Lunella Biotech, Inc. | Senolytic compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK149776C (da) * | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| US6805880B1 (en) * | 1999-08-20 | 2004-10-19 | Ferrosan A/S | Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress |
| RU2223103C1 (ru) * | 2002-07-17 | 2004-02-10 | Открытое акционерное общество "Биосинтез" | Фармацевтическая композиция, обладающая антибактериальным действием |
| CN1837229A (zh) * | 2005-08-05 | 2006-09-27 | 济南思创生物技术有限公司 | 克拉霉素衍生物及其制备方法和药物应用 |
| US7282225B1 (en) * | 2006-09-27 | 2007-10-16 | Occular Technologies, Inc. | Composition and methods for improving retinal health |
| US8168597B2 (en) * | 2008-10-22 | 2012-05-01 | Inspire Pharmaceuticals, Inc. | Method for treating cystic fibrosis |
| WO2012112945A1 (en) * | 2011-02-18 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Use of matrix metalloproteinase inhibitors to treat tuberculosis |
| WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
| US9775855B2 (en) * | 2011-09-14 | 2017-10-03 | Thomas J. Lewis | Compositions comprising macrolide and tetracycline and their uses |
| GB201217310D0 (en) * | 2012-09-27 | 2012-11-14 | C10 Pharma As | Compounds |
| CN103536530A (zh) * | 2013-10-30 | 2014-01-29 | 王玉万 | 盐酸多西环素长效注射剂及制备方法 |
| US11311501B2 (en) * | 2017-03-15 | 2022-04-26 | Lunella Biotech, Inc. | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast |
| WO2018193116A1 (en) * | 2017-04-20 | 2018-10-25 | Novintum Biotechnology Gmbh | Azithromycin derivatives containing a phosphonium ion as anticancer agents |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| PH12019502594A1 (en) * | 2017-05-19 | 2020-10-26 | Lunella Biotech Inc | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11883497B2 (en) * | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| KR20210072026A (ko) * | 2018-10-02 | 2021-06-16 | 루넬라 바이오테크 인코포레이티드 | 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체 |
| AU2019403048B2 (en) * | 2018-12-17 | 2025-01-23 | Lunella Biotech, Inc. | Triple combination therapies for targeting mitochondria and killing cancer stem cells |
-
2019
- 2019-12-16 AU AU2019402099A patent/AU2019402099B2/en active Active
- 2019-12-16 SG SG11202106532WA patent/SG11202106532WA/en unknown
- 2019-12-16 MX MX2021007347A patent/MX2021007347A/es unknown
- 2019-12-16 KR KR1020217022471A patent/KR20210104830A/ko not_active Ceased
- 2019-12-16 CN CN201980091563.7A patent/CN113453690A/zh active Pending
- 2019-12-16 CR CR20210351A patent/CR20210351A/es unknown
- 2019-12-16 BR BR112021011964-7A patent/BR112021011964A2/pt unknown
- 2019-12-16 JP JP2021534981A patent/JP7641897B2/ja active Active
- 2019-12-16 PE PE2021000909A patent/PE20220499A1/es unknown
- 2019-12-16 WO PCT/US2019/066553 patent/WO2020131704A1/en not_active Ceased
- 2019-12-16 EP EP19900644.6A patent/EP3897659A4/en active Pending
- 2019-12-16 CA CA3123850A patent/CA3123850A1/en active Pending
- 2019-12-16 US US17/414,853 patent/US11918597B2/en active Active
-
2021
- 2021-06-15 IL IL284059A patent/IL284059B2/en unknown
- 2021-06-17 CL CL2021001617A patent/CL2021001617A1/es unknown
- 2021-06-17 DO DO2021000123A patent/DOP2021000123A/es unknown
- 2021-06-17 PH PH12021551435A patent/PH12021551435A1/en unknown
- 2021-06-21 ZA ZA2021/04254A patent/ZA202104254B/en unknown
- 2021-07-08 CO CONC2021/0009008A patent/CO2021009008A2/es unknown
- 2021-07-16 EC ECSENADI202152757A patent/ECSP21052757A/es unknown
-
2024
- 2024-01-29 US US18/425,427 patent/US20240316086A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3123850A1 (en) | 2020-06-25 |
| PH12021551435A1 (en) | 2021-12-06 |
| ECSP21052757A (es) | 2021-08-31 |
| US20240316086A1 (en) | 2024-09-26 |
| CO2021009008A2 (es) | 2021-10-20 |
| AU2019402099B2 (en) | 2025-01-23 |
| JP2022514739A (ja) | 2022-02-15 |
| MX2021007347A (es) | 2021-07-15 |
| ZA202104254B (en) | 2023-01-25 |
| EP3897659A4 (en) | 2022-09-07 |
| JP7641897B2 (ja) | 2025-03-07 |
| IL284059B2 (en) | 2023-08-01 |
| WO2020131704A8 (en) | 2021-07-29 |
| WO2020131704A1 (en) | 2020-06-25 |
| IL284059A (en) | 2021-08-31 |
| CR20210351A (es) | 2021-07-14 |
| SG11202106532WA (en) | 2021-07-29 |
| US20220016151A1 (en) | 2022-01-20 |
| CL2021001617A1 (es) | 2022-01-14 |
| EP3897659A1 (en) | 2021-10-27 |
| BR112021011964A2 (pt) | 2021-09-08 |
| US11918597B2 (en) | 2024-03-05 |
| AU2019402099A1 (en) | 2021-07-08 |
| PE20220499A1 (es) | 2022-04-07 |
| IL284059B1 (en) | 2023-04-01 |
| KR20210104830A (ko) | 2021-08-25 |
| CN113453690A (zh) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21052757A (es) | Terapias de combinación triple para anti-envejecimiento | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| CL2018003588A1 (es) | Uso de inhibidores de miostatina y terapias de combinación. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
| CO2021002222A2 (es) | Mezclas antimicrobianas que comprenden al menos un derivado de hidroxifenona | |
| CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
| CL2016001131A1 (es) | Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones. | |
| MX2018015761A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017007829A (es) | Composicion antimicrobiana. | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| BR112017007543A2 (pt) | peptídeos com propriedades anti-inflamatórias | |
| CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
| IL280162A (en) | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria | |
| BR112017011792A2 (pt) | antena de abertura apoiada em uma cavidade | |
| AR107886A1 (es) | Composiciones para el tratamiento del cabello | |
| MX2015014713A (es) | Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cancer. | |
| CL2021000529A1 (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| MX2016015092A (es) | Inhibidor de proliferacion de celulas madre cancerosas. | |
| CO2019015102A2 (es) | Nuevos derivados de xantina sustituidos |